This comprehensive medical market and technology report provides an overview and in-depth market analysis of liquid biopsy products used in the field of oncology. In 2020, the global market for liquid biopsy products for oncology applications was valued at approximately $1.9bn. This is a rapidly evolving and fast-growing market. During the 2020-25 forecast period, the market is projected to increase at a CAGR of 26.8%. While liquid biopsies are utilized for other indications (eg detection of myocardial infarction and prenatal testing), the publisher estimates that liquid biopsy assays for oncology account for over 90% of total liquid biopsy sales.
Market forecasts for this report are segmented based on the type of biomarker utilized and the main clinical applications for liquid biopsy (ie screening, therapy selection, molecular minimal residual disease monitoring, and biopharma research/product development).
This report provides the following information:
- An epidemiological overview, including incidence data, for the most common types of cancer
- Competitive analysis
- Insight into factors driving and limiting market growth
- Market forecasts
- Overview of FDA-approved liquid biopsy companion diagnostics for cancer therapy selection
Geographic regions covered by this report include North America, Europe, Asia-Pacific (APAC), and the rest of the world (RoW).
